Table 3. Laboratory findings in critical patients with HFRS complicated by ARDS during the acute stage.

Variables	Survivors (n = 27)	Non-survivors (n = 21)	p value•
Maximum leukocyte counts, ×109/L	35.95±15.49*	46.93±22.45*	0.051
Nadir PLT, ×109/L	11.81±12.93**	15.29±10.94**	0.330
Maximum HGB, g/L	170.96±22.29*	162.48±19.94	0.178
Maximum ALT, U/L	208.07±256.04*	350.33±324.42*	0.096
Nadir serum ALB, g/L	22.74±5.14**	21.31±5.16**	0.344
Maximum Scr, µmol/L	788.95±236.27*	411.88±197.49*	<0.001
Maximum UA, µmol/L	543.20±213.00*	433.76±154.57	0.054
Maximum glucose, mmol/L	13.58±6.30*	14.52±8.30*	0.656
Longest PT, sec	15.95±3.87*	23.73±11.32*	0.006
Longest APTT, sec	50.92±16.16*	63.58±20.13*	0.020
Longest TT, sec	25.19±6.79*	26.44±7.49*	0.554
Minimum Fib, g/L	1.63±0.64**	1.13±0.40**	0.003
Maximum AST, U/L	370.33±406.15*	1271.9±1531.14*	0.015

Reference values: Leukocyte count (3.2–9.7)×109/L; PLT (100–300)×109/L; HGB (120–160) g/L (male), (110–150) g/L (female); ALT (4–44) U/L; AST (8–38) U/L; serum ALB (35–55) g/L; serum Cr (53–97) µmol/L (male), (35–71) µmol/L (female); UA (210–430) µmol/L (male), (150–360) µmol/L (female); glucose (3.89–6.11) mmol/L; PT (8.8–13.8) sec; APTT (25.1–36.5) sec; TT (10.3–16.6) sec, and Fib (2.38–4.98) g/L.

PLT, platelet; HGB, hemoglobin; ALT, alanine aminotransferase; ALB, albumin; Scr, serum creatinine; UA, uric acid; PT, prothrombin time; APTT, activated partial thromboplastin time; TT, thrombin time; Fib, fibrinogen;AST, aspartate aminotransferase.

^•Survivors vs. non-survivors.

* Higher or longer than the reference value, P<0.05.

** Lower than the reference value, P<0.05.